Correction to: Expressive language sampling as a source of outcome measures for treatment studies in fragile X syndrome: feasibility, practice effects, test-retest reliability, and construct validity
- PMID: 32241250
- PMCID: PMC7119274
- DOI: 10.1186/s11689-020-09314-5
Correction to: Expressive language sampling as a source of outcome measures for treatment studies in fragile X syndrome: feasibility, practice effects, test-retest reliability, and construct validity
Abstract
In the original publication of this article [1], the author name Leonard Abbeduto was misspelled as Leonardkk Abbeduto. The original article has been corrected.
Erratum for
-
Expressive language sampling as a source of outcome measures for treatment studies in fragile X syndrome: feasibility, practice effects, test-retest reliability, and construct validity.J Neurodev Disord. 2020 Mar 24;12(1):10. doi: 10.1186/s11689-020-09313-6. J Neurodev Disord. 2020. PMID: 32204695 Free PMC article.
References
-
- Abbeduto L, Berry-Kravis E, Sterling A, Sherman S, Edgin JO, McDuffie A, Hoffmann A, Hamilton D, Nelson M, Aschkenasy J, Thurman AJ. Expressive language sampling as a source of outcome measures for treatment studies in fragile X syndrome: feasibility, practice effects, test-retest reliability, and construct validity. J Neurodevelop Disord. 2020;12:10. doi: 10.1186/s11689-020-09313-6. - DOI - PMC - PubMed
